Hypothesis

Partial attenuation of the GH/IGF-1 axis reprograms immune cell metabolism to enhance senescent cell clearance, thereby reducing inflammaging and extending healthspan.

Mechanistic Rationale

GH/IGF-1 signaling activates mTORC1 in macrophages and neutrophils, suppressing autophagy and promoting a pro‑inflammatory phenotype. Moderate reduction of this axis lowers mTORC1 activity, boosting AMPK‑driven autophagy and NAD+ synthesis, which shifts macrophages toward a pro‑resolving, senolytic state (M2‑like) capable of efficiently phagocytosing senescent adipocytes and fibroblasts. Simultaneously, reduced IGF‑1 diminishes STAT3 signaling in neutrophils, limiting NETosis‑mediated tissue damage. This metabolic shift mirrors the beneficial immune profile seen with estrogen‑based HRT but originates from somatopause modulation rather than sex‑steroid pathways [5][6][7].

Predictions

1. Mice with inducible, liver‑specific GHR knockdown (≈50% circulating IGF‑1 reduction) will show increased autophagic flux (LC3‑II/I ratio) in adipose‑tissue macrophages compared with wild‑type aged controls.
2. These mice will exhibit lower frequencies of p16^Ink4a^+ senescent cells in visceral fat and liver, accompanied by decreased serum IL‑6, TNF‑α, and IL‑1β, reflecting reduced inflammaging [1].
3. Flow cytometry will reveal a higher CD206^+ CD86^− (M2‑like) macrophage ratio and reduced Ly6C^hi inflammatory monocytes, correcting the age‑shifted monocyte phenotypes noted in aging [1].
4. Functional assays will demonstrate enhanced phagocytosis of p16^Ink4a^+ beads ex vivo, indicative of restored immune surveillance against senescent cells.
5. Consequently, treated mice will improve glucose tolerance, grip strength, and median lifespan relative to controls, consistent with the longevity seen in GH‑deficient models [4].

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice; groups: (i) wild‑type vehicle, (ii) liver‑specific GHR‑flox crossed with Alb‑CreERT2 treated with tamoxifen (inducible ~50% IGF‑1 drop), (iii) positive control receiving low‑dose estrogen‑HRT.
• Interventions: Tamoxifen at 20 months, maintain for 6 months.
• Readouts: (a) Serum IGF‑1, cytokines (ELISA); (b) Adipose macrophage autophagy (LC3‑II/I western blot, p62 degradation); (c) Senescent cell burden (p16^Ink4a^ immunostaining, flow cytometry); (c) Immune phenotyping (flow cytometry for monocytes, macrophage M1/M2 markers); (d) Phagocytosis assay using fluorescent senescent cell lysates; (e) Metabolic tests (GTT, insulin tolerance); (f) Frailty index and survival monitoring.

Potential Outcomes and Interpretation

• If predictions hold, moderate GH/IGF-1 attenuation enhances immune‑mediated senolysis, supporting the hypothesis that somatopause can be therapeutically harnessed to mitigate inflammaging without compromising host defense.
• If autophagic flux does not increase or senescent cell burden rises, the hypothesis is falsified, suggesting that GH/IGF-1 reduction alone insufficient to re‑program immune senescence or that immune dysfunction drives aging independently of the somatopause axis.
• An intermediate outcome (improved metabolism but no change in senescence) would indicate that GH/IGF-1 effects are primarily metabolic, prompting refinement of the mechanistic link.

This framework directly tests whether tuning the somatopause axis can re‑educate the immune system to act as a senolytic rather than a senescent‑promoting force, addressing the gap noted in the literature regarding immune tradeoffs of GH/IGF-1 modulation.